

Vanthida Huang

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1450645/publications.pdf>

Version: 2024-02-01

30
papers

689
citations

567281

15
h-index

552781

26
g-index

31
all docs

31
docs citations

31
times ranked

1036
citing authors

#	ARTICLE	IF	CITATIONS
1	Multicenter Cohort Study of Ceftaroline Versus Daptomycin for Treatment of Methicillin-Resistant <i>Staphylococcus aureus</i> Bloodstream Infection. <i>Open Forum Infectious Diseases</i> , 2022, 9, ofab606.	0.9	12
2	Optimizing outcomes using vancomycin therapeutic drug monitoring in patients with MRSA bacteremia: trough concentrations or area under the curve?. <i>Diagnostic Microbiology and Infectious Disease</i> , 2021, 101, 115442.	1.8	4
3	The Risk of Acute Kidney Injury in Critically Ill Patients Receiving Concomitant Vancomycin With Piperacillin-Tazobactam or Cefepime. <i>Journal of Intensive Care Medicine</i> , 2020, 35, 1434-1438.	2.8	18
4	Utilization of Augmented Renal Clearance in Trauma Intensive Care Scoring System to Improve Vancomycin Dosing in Trauma Patients at Risk for Augmented Renal Clearance. <i>Surgical Infections</i> , 2020, 21, 43-47.	1.4	8
5	Perspectives: potential therapeutic options for SARS-CoV-2 patients based on feline infectious peritonitis strategies: central nervous system invasion and drug coverage. <i>International Journal of Antimicrobial Agents</i> , 2020, 55, 105964.	2.5	9
6	Glycopeptide Hypersensitivity and Adverse Reactions. <i>Pharmacy (Basel, Switzerland)</i> , 2020, 8, 70.	1.6	12
7	The Emerging Role of β -Lactams in the Treatment of Methicillin-Resistant <i>Staphylococcus aureus</i> Bloodstream Infections. <i>Antimicrobial Agents and Chemotherapy</i> , 2020, 64, .	3.2	23
8	Multicenter Study of the Real-World Use of Ceftaroline versus Vancomycin for Acute Bacterial Skin and Skin Structure Infections. <i>Antimicrobial Agents and Chemotherapy</i> , 2019, 63, .	3.2	1
9	Antibiotic Hypersensitivity Mechanisms. <i>Pharmacy (Basel, Switzerland)</i> , 2019, 7, 122.	1.6	22
10	Ceftaroline fosamil monotherapy for methicillin-resistant <i>Staphylococcus aureus</i> bacteremia: a comparative clinical outcomes study. <i>International Journal of Infectious Diseases</i> , 2017, 57, 27-31.	3.3	40
11	Multicenter Study of Outcomes with Ceftazidime-Avibactam in Patients with Carbapenem-Resistant Enterobacteriaceae Infections. <i>Antimicrobial Agents and Chemotherapy</i> , 2017, 61, .	3.2	92
12	Risk Factors for 30-Day Mortality in Patients with Methicillin-Resistant <i>Staphylococcus aureus</i> Bloodstream Infections. <i>International Journal of Infectious Diseases</i> , 2017, 61, 3-6.	3.3	19
13	Vancomycin Serum Trough Levels and Outcomes in Patients With Methicillin-Resistant <i>Staphylococcus aureus</i> Bacteremia. <i>Open Forum Infectious Diseases</i> , 2016, 3, .	0.9	0
14	Emerging Issues and Treatment Strategies in Carbapenem-Resistant Enterobacteriaceae (CRE). <i>Current Infectious Disease Reports</i> , 2016, 18, 48.	3.0	16
15	Resistance to Non-glycopeptide Agents in Serious <i>Staphylococcus aureus</i> Infections. <i>Current Infectious Disease Reports</i> , 2016, 18, 47.	3.0	7
16	Pharmacokinetic and Pharmacodynamic Evaluation of Doripenem in Critically Ill Trauma Patients with Sepsis. <i>Surgical Infections</i> , 2016, 17, 675-682.	1.4	1
17	Cleaning and disinfecting environmental surfaces in health care: Toward an integrated framework for infection and occupational illness prevention. <i>American Journal of Infection Control</i> , 2015, 43, 424-434.	2.3	125
18	<i>Neisseria gonorrhoeae</i> and fosfomycin: Past, present and future. <i>International Journal of Antimicrobial Agents</i> , 2015, 46, 290-296.	2.5	12

#	ARTICLE	IF	CITATIONS
19	Evaluation of in vitro susceptibility trends to vancomycin and daptomycin by strain type of <i>Staphylococcus aureus</i> causing bloodstream infections. <i>Journal of Global Antimicrobial Resistance</i> , 2014, 2, 280-285.	2.2	1
20	Characterization of heterogeneous vancomycin-intermediate resistance, MIC and accessory gene regulator (<i>agr</i>) dysfunction among clinical bloodstream isolates of <i>Staphylococcus aureus</i> . <i>BMC Infectious Diseases</i> , 2011, 11, 287.	2.9	29
21	Evaluation of dalbavancin, tigecycline, minocycline, tetracycline, teicoplanin and vancomycin against community-associated and multidrug-resistant hospital-associated methicillin-resistant <i>Staphylococcus aureus</i> . <i>International Journal of Antimicrobial Agents</i> , 2010, 35, 25-29.	2.5	18
22	Characterisation of a <i>Staphylococcus aureus</i> strain with progressive loss of susceptibility to vancomycin and daptomycin during therapy. <i>International Journal of Antimicrobial Agents</i> , 2009, 33, 564-568.	2.5	57
23	Evaluation of a Formulary Change on Outcome of Infection and Antimicrobial Resistance in a Medical Intensive Care Unit. <i>Infectious Diseases in Clinical Practice</i> , 2006, 14, 360-364.	0.3	0
24	Risk of Serotonin Syndrome with Concomitant Administration of Linezolid and Serotonin Agonists. <i>Pharmacotherapy</i> , 2006, 26, 1784-1793.	2.6	67
25	Evaluation of daptomycin activity against <i>Staphylococcus aureus</i> in an in vitro pharmacodynamic model under normal and simulated impaired renal function. <i>Journal of Antimicrobial Chemotherapy</i> , 2006, 57, 116-121.	3.0	25
26	Poly-L-lactic Acid for Facial Lipoatrophy in HIV. <i>Annals of Pharmacotherapy</i> , 2006, 40, 1602-1606.	1.9	20
27	Methicillin-Resistant <i>Staphylococcus aureus</i> in the Community. <i>Infectious Diseases in Clinical Practice</i> , 2005, 13, 93-95.	0.3	4
28	Pharmacodynamics of Cefepime Alone and in Combination with Various Antimicrobials against Methicillin-Resistant <i>Staphylococcus aureus</i> in an In Vitro Pharmacodynamic Infection Model. <i>Antimicrobial Agents and Chemotherapy</i> , 2005, 49, 302-308.	3.2	34
29	In Vitro Activities of a Novel Cephalosporin, CB-181963 (CAB-175), against Methicillin-Susceptible or -Resistant <i>Staphylococcus aureus</i> and Glycopeptide-Intermediate Susceptible <i>Staphylococci</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2004, 48, 2719-2723.	3.2	11
30	Penicillin plus Ceftriaxone versus Ampicillin plus Ceftriaxone Synergistic Potential against Clinical <i>Enterococcus faecalis</i> Blood Isolates. <i>Microbiology Spectrum</i> , 0, , .	3.0	2